Tag: Epidermolysis Bullosa
Chiesi Farmaceutici to acquire biopharma company Amryt Pharma for $1.5bn
Chiesi Farmaceutici, an Italian biopharmaceuticals and healthcare group, has agreed to acquire Amryt Pharma, a commercial-stage biopharmaceutical company, in an all-cash transaction valued at around ... Read More
TWi Biotechnology initiates AC-203 phase 2 trial for Epidermolysis Bullosa
TWi Biotechnology, a Taiwanese biotech company, has announced the enrollment of the first patient in a phase 2 trial evaluating AC-203 for the treatment of ... Read More